Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer

Fig. 4

OICR-9429 suppresses tumour growth and enhances cisplatin efficacy in bladder cancer cells in vivo. a. The volume of tumours in the indicated groups was measured every 3 days. The average tumour volume is shown as the mean ± SD of six mice. b. Representative images of dissected tumours treated with control solvent, OICR-9429 (60 mg/kg), cisplatin (4 mg/kg), or a combination of small dose OICR-9429 (30 mg/kg) and cisplatin (2.5 mg/kg). c. Tumour weights were measured after the tumours were surgically dissected. d. The expression of Ki67 in the tumour was examined by IHC. Histogram shows the H-score of Ki67 IHC in each group. Scale bars, 50 μm (black). e. Tumour apoptosis was detected by TUNEL assay. Histogram shows the proportion of TUNEL-positive cells in each group. Scale bars, 100 μm (white). *p < 0.05; **p < 0.01

Back to article page